Literature DB >> 16729298

The natural history of compensated cirrhosis due to hepatitis C virus: A 17-year cohort study of 214 patients.

Angelo Sangiovanni1, Gian Maria Prati, Pierangelo Fasani, Guido Ronchi, Raffaella Romeo, Matteo Manini, Ersilio Del Ninno, Alberto Morabito, Massimo Colombo.   

Abstract

Large databases of consecutive patients followed for sufficiently long periods are needed to establish the rates, chronology, and hierarchy of complications of cirrhosis as well as the importance of other potential causes of liver disease. In accordance with this goal, a cohort of patients with compensated cirrhosis due to hepatitis C virus (HCV) was followed for 17 years. Two hundred and fourteen HCV RNA-seropositive patients with Child-Pugh class A cirrhosis who had no previous clinical decompensation were prospectively recruited and followed up with periodic clinical and abdominal ultrasound examinations. During 114 months (range 1-199), hepatocellular carcinoma (HCC) developed in 68 (32%), ascites in 50 (23%), jaundice in 36 (17%), upper gastrointestinal bleeding in 13 (6%), and encephalopathy in 2 (1%), with annual incidence rates of 3.9%, 2.9%, 2.0%, 0.7%, and 0.1%, respectively. Clinical status remained unchanged in 154 (72%) and progressed to Child-Pugh class B in 45 (21%) and class C in 15 (7%). HCC was the main cause of death (44%) and the first complication to develop in 58 (27%) patients, followed by ascites in 29 (14%), jaundice in 20 (9%), and upper gastrointestinal bleeding in 3 (1%). The annual mortality rate was 4.0% per year and was higher in patients with other potential causes of liver disease than in those without them (5.7% vs. 3.6%; P = .04). In conclusion, hepatitis C-related cirrhosis is a slowly progressive disease that may be accelerated by other potential causes of liver disease. HCC was the first complication to develop and the dominant cause for increased mortality.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16729298     DOI: 10.1002/hep.21176

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  139 in total

Review 1.  Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.

Authors:  Andrew J Muir
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

Review 2.  Training for a career in hepatology: which path to take?

Authors:  Bruce A Luxon
Journal:  Curr Gastroenterol Rep       Date:  2010-02

3.  Hepatitis C virus replication and potential targets for direct-acting agents.

Authors:  Jacqueline G O'Leary; Gary L Davis
Journal:  Therap Adv Gastroenterol       Date:  2010-01       Impact factor: 4.409

Review 4.  Treatment of intermediate-stage hepatocellular carcinoma.

Authors:  Alejandro Forner; Marine Gilabert; Jordi Bruix; Jean-Luc Raoul
Journal:  Nat Rev Clin Oncol       Date:  2014-08-05       Impact factor: 66.675

5.  Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States.

Authors:  Jagpreet Chhatwal; Shannon A Ferrante; Cliff Brass; Antoine C El Khoury; Margaret Burroughs; Bruce Bacon; Rafael Esteban-Mur; Elamin H Elbasha
Journal:  Value Health       Date:  2013 Sep-Oct       Impact factor: 5.725

6.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 7.  Does Hepatocellular Carcinoma Surveillance Increase Survival in At-Risk Populations? Patient Selection, Biomarkers, and Barriers.

Authors:  Lisa X Deng; Neil Mehta
Journal:  Dig Dis Sci       Date:  2020-12       Impact factor: 3.199

8.  Peripheral virus-specific T-cell interleukin-10 responses develop early in acute hepatitis C infection and become dominant in chronic hepatitis.

Authors:  David E Kaplan; Fusao Ikeda; Yun Li; Nobuhiro Nakamoto; Sutharsan Ganesan; Mary E Valiga; Frederick A Nunes; K Rajender Reddy; Kyong-Mi Chang
Journal:  J Hepatol       Date:  2008-03-07       Impact factor: 25.083

9.  Does protracted antiviral therapy impact on HCV-related liver cirrhosis progression?

Authors:  Giovanni Tarantino; Antonio Gentile; Domenico Capone; Vincenzo Basile; Marianna Tarantino; Matteo-Nicola-Dario Di Minno; Alberto Cuocolo; Paolo Conca
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

Review 10.  Chronic hepatitis C genotype 1 virus: who should wait for treatment?

Authors:  Cristiane Valle Tovo; Angelo Alves de Mattos; Paulo Roberto Lerias de Almeida
Journal:  World J Gastroenterol       Date:  2014-03-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.